The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data.
The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.
Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/1111
North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2019, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.
Further key findings from the report suggest
-
- Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT’s lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.
- North American market is forecasted to grow at a CAGR of 53% in the coming years. The disease is considered to be one of the leading causes of cirrhosis in adults in the U.S. High incidence of diabetes and obesity in the region are considered to be the main reason behind increasing incidence of NASH. Based on American Liver Foundation’s National Medical Advisory Committee currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of the NASH patients suffer from either obesity or diabetes.
The ongoing pandemic is significantly changing the dynamics of the pharma and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is expected to open lucrative growth opportunities for market players in the coming years.
Competitive Landscape:
The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market.
Top Companies Profiled in the Report:
Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics
To know more about the report, visit @ https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market
Non-Alcoholic SteatoHepatitis (NASH) Market Segmentation:
Disease Cause Outlook (Revenue, USD Million; 2018-2028)
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Drug Type Outlook (Revenue, USD Million; 2018-2028)
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
Regional Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin America (Brazil, Rest of LATAM)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/1111
This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.
Explore Latest Trending Research Reports By Reports and Data:
Cell Signaling Market By Product Type (Endocrine Signaling, Paracrine Signaling, Autocrine Signaling, Juxtacrine Signaling, and Others), By Product (Consumables and Instruments), By Application (Research and Medical), By Pathway (Akt, AMPK, ErbB/HER, Hedgehog, JAK/SAT, NF-eB, Notch, and Others) By Technology (Microscopy, Western Blotting, Flow Cytometry, Immunohistochemistry, ELISA, Mass Spectrometry, and Other) and By Region Forecast to 2028 Download PDF Brochure
Medical Armrest Market Size, Share And Industry Analysis By Product Type (Height Adjustable and Fixed), By Application (Operating Table, Medical Beauty Organizations, Arm Surgery, Commode Chairs, and Others), and Region Forecast To 2028 Download PDF Brochure
Advanced Infusion Systems Market By Type (Disposable, Elastomeric, Ambulatory, Volumetric, Patient Controlled Analgesia Pump, and Syringe); By Application (Chemotherapy, Diabetes, Pain Management, Asthma, and Clinical Nutrition); and By Region Forecast To 2028 By Type (Disposable, Elastomeric, Ambulatory, Volumetric, Patient Controlled Analgesia Pump, and Syringe); By Application (Chemotherapy, Diabetes, Pain Management, Asthma, and Clinical Nutrition); and By Region Forecast To 2028 Download PDF Brochure
Chiropractic Market Size, Share, And Industry Analysis By Product Type (Maintenance Care, Relief Care, and Corrective Care); By End-user (Hospitals, Clinics, In-home Consultations, and Wellness Centres), and By Region Forecast to 2028 Download PDF Brochure
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Read the innovative blog at https://www.reportsanddata.com/blogs
Check out our upcoming research report at https://www.reportsanddata.com/upcoming-reports